The government will consider including India's first indigenous anti-COVID drug 2-DG in the national COVID-19 treatment protocol after examining the data of the medicine, officials said Tuesday.
At a press conference, NITI Aayog member (health) Dr V K Paul said Drugs Controller General of India (DCGI) has granted permission for emergency use of the drug after looking at the data.
The drug 2-deoxy-D-glucose has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), along with Dr Reddy's Laboratories (DRL), Hyderabad.
In response to a question, Paul said, "We will examine in COVID-19 National Task Force meeting for adding the drug in the national treatment protocol."
The first batch of the adjunct COVID therapy anti-COVID drug was released by Defence Minister Rajnath Singh and handed over to Health Minister Harsh Vardhan here on Monday.
One box each of the sachets of the drug was handed over to Delhi AIIMS Director Dr Randeep Guleria and Lt Gen Sunil Kant of Armed Forces Medical Services (AFMS).
More will be handed over to different hospitals across the country for emergency use.
Vardhan termed 2-DG an important development by DRDO and DRL that will reduce the recovery time and oxygen dependency in COVID-19 patients.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.